Fanchuang Medical Biotechnology Co., Ltd.


Customer Demand Is The Best Source Of Innovation

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Intermediates

Avibactam Pharmaceutical Intermediates CAS NO 1192500-31-4 Cas 1192491-61-4

Great Service Great Quality.

—— Carl Balfou

I appreciate you because you are so friendly and helpful. You really are a real pleasure to work with so polite and enjoyable to work with.

—— Jeff Rader

You are the sweetest, most caring service possible.

—— Luis Acosta

I'm Online Chat Now

Avibactam Pharmaceutical Intermediates CAS NO 1192500-31-4 Cas 1192491-61-4

Large Image :  Avibactam Pharmaceutical Intermediates CAS NO 1192500-31-4 Cas 1192491-61-4

Product Details:

Place of Origin: China
Brand Name: R&M
Certification: ISO 9001, USP, GMP
Model Number: 01

Payment & Shipping Terms:

Minimum Order Quantity: 1g
Price: negotiation
Packaging Details: vaccum packing of aluminum foil bag
Detailed Product Description
ProName: Avibactam CasNo: 1192491-61-4
Appearance: White Or Off-white Powder Formula: C7H11N3O6S
Molar Mass: 265.24 G/mol Storage: Store The Shade
High Light:

active pharmaceutical ingredients


bulk drug intermediates

Clinical data
Trade namesAvycaz (formulated with ceftazidime)
License data
  • EU EMA: by INN

  • US: B (No risk in non-human studies)

Routes of
ATC code
  • None
Legal status
Legal status
  • US: ℞-only

Pharmacokinetic data
Bioavailability100% (intravenous)
Protein binding5.7–8.2%[1]
Onset of actionIncreases in proportion to dose
ExcretionRenal (97%)
IUPAC name[hide]
  • [(2S,5R)-2-Carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
CAS Number
  • 1192500-31-4

PubChem CID
  • 9835049

  • 8010770

  • D10340

  • CHEBI:85984 [Yes]

  • CHEMBL1689063

Chemical and physical data
Molar mass265.24 g/mol
3D model (JSmol)
  • Interactive image

  • [C@]12C[N@]([C@@H](CC1)C(N)=O)C(=O)N2OS(O)(=O)=O
  • InChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1

Avibactam is a non-β-lactam β-lactamase inhibitor[2] developed by Actavis (now [Teva]) jointly with AstraZeneca. A new drug application for avibactam in combination with ceftazidime (branded as Avycaz) was approved by the FDA on February 25, 2015, for treating complicated urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant Gram-negative bacterial pathogens.
Increasing resistance to cephalosporins among Gram-(−) bacterial pathogens, especially among hospital-acquired infections, results in part from the production of β-lactamase enzymes that deactivate these antibiotics. While the co-administration of a β-lactamase inhibitor can restore antibacterial activity to the cephalosporin, previously approved β-lactamase inhibitors such as tazobactam andclavulanic acid do not inhibit important classes of β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs), New Delhi metallo-β-lactamase 1 (NDM-1), and AmpC-type β-lactamases. Whilst avibactam inhibits class A (KPCs, CTX-M, TEM, SHV), class C (AmpC), and, some, class D serine β-lactamases (such as OXA-23, OXA-48), it has been reported to be a poor substrate/weak inhibitor of class B metallo-β-lactamases, such as VIM-2, VIM-4, SPM-1, BcII, NDM-1, Fez-1.

Contact Details
Fanchuang Medical Biotechnology Co., Ltd.

Contact Person: admin

Tel: +8615731109960

Send your inquiry directly to us Message not be empty!